MeiraGTx is a clinical-stage genetic medicine company developing gene therapies for inherited and acquired diseases, with a strong focus on ocular disorders as well as programs in salivary gland and central nervous system conditions. It builds and operates manufacturing capability for viral vectors, a scarce and strategic asset in gene therapy. Revenue has been limited and often collaboration-driven while late-stage candidates advance toward potential commercialization.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 3.7 | — | -38.8 | — |
| Q3 2025 | 0.4 | — | -50.5 | — |
| Q4 2025 | 75.4 | — | 15.1 | — |
| Q1 2026 | 0.3 | — | -46.3 | — |
| Q2 2026 | 321.4 | 8,608.6% | 160.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: QuidelOrtho Corporation (QDEL), Theravance Biopharma, Inc. (TBPH), Beta Bionics, Inc. (BBNX), First Financial Corporation (THFF), Astec Industries, Inc. (ASTE), Daktronics, Inc. (DAKT)